Mocci, Giammarco
 Distribuzione geografica
Continente #
EU - Europa 436
NA - Nord America 305
AS - Asia 50
Totale 791
Nazione #
US - Stati Uniti d'America 305
DE - Germania 253
SE - Svezia 43
UA - Ucraina 38
CN - Cina 33
IT - Italia 31
FR - Francia 22
GB - Regno Unito 22
IE - Irlanda 10
FI - Finlandia 8
IN - India 7
RU - Federazione Russa 4
IR - Iran 2
JP - Giappone 2
TR - Turchia 2
BG - Bulgaria 1
HU - Ungheria 1
IL - Israele 1
KR - Corea 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
SG - Singapore 1
TW - Taiwan 1
Totale 791
Città #
Chandler 70
Jacksonville 33
Dearborn 23
Nürnberg 22
San Mateo 21
Ashburn 18
New York 16
Cattolica 12
Dublin 10
Lancaster 8
Munich 8
Bremen 7
Milan 7
Wilmington 6
Ann Arbor 5
Houston 5
Nanjing 5
Beijing 4
Boston 4
Detroit 4
Lawrence 4
Leawood 4
Rome 4
Shanghai 4
Tianjin 4
Woodbridge 4
Jiaxing 3
Nanchang 3
Princeton 3
Changsha 2
Florence 2
Izmir 2
Marseille 2
Millbury 2
Redwood City 2
Seattle 2
University Park 2
Amsterdam 1
Andover 1
Ardabil 1
Augusta 1
Bucharest 1
Budapest 1
Changchun 1
Clearwater 1
Costa Mesa 1
Easton 1
Edinburgh 1
Fairfield 1
Guangzhou 1
Hangzhou 1
Hebei 1
Helsinki 1
Kish 1
Kraków 1
Kyiv 1
Los Angeles 1
Monmouth Junction 1
Mountain View 1
Ningbo 1
Norwalk 1
Novara 1
Paris 1
Quzhou 1
Redmond 1
San Jose 1
Seoul 1
Shenyang 1
Singapore 1
Sofia 1
Taipei 1
Tettnang 1
Washington 1
Totale 373
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 147
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 131
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 130
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 108
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 100
Use of infliximab in particular clinical settings: management based on current evidence. 94
Management of perianal fistulas in Crohn's disease: an up-to-date review 69
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 6
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 5
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 4
Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists 1
Totale 795
Categoria #
all - tutte 2.107
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.107


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 0 18 7
2019/2020148 22 8 20 4 12 26 15 5 9 6 12 9
2020/202163 1 8 1 7 11 1 7 2 9 0 15 1
2021/202277 10 7 2 9 2 0 0 18 0 1 8 20
2022/2023160 16 24 10 37 10 19 3 11 23 0 4 3
2023/202469 4 17 0 4 1 12 4 8 9 10 0 0
Totale 795